• Amarin Corp. plc, of Dublin, said it was notified by the FDA that its scheduled advisory committee meeting Oct. 16 to discuss the proposed Vascepa (icosapent ethyl) ANCHOR indication will take place as planned, despite the federal government lapse in appropriations.